Discovery of Ebselen as an Inhibitor of 6PGD for Suppressing Tumor Growth
Authors Feng Q, Li X, Sun W, Li Y, Yuan Y, Guan B, Zhang S
Received 25 March 2020
Accepted for publication 9 July 2020
Published 5 August 2020 Volume 2020:12 Pages 6921—6934
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Yong Teng
Qi Feng,1 Xiuru Li,1 Wenjing Sun,1 Yubo Li,2 Yu Yuan,2 Baozhang Guan,1 Shuai Zhang3
1The First Affiliated Hospital, Biomedical Translational Research Institute, Jinan University, Guangzhou, Guangdong 510632, People’s Republic of China; 2Tianjin State Key Laboratory of Modern Chinese Medicine, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, People’s Republic of China; 3School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, People’s Republic of China
Correspondence: Shuai Zhang; Baozhang Guan Email firstname.lastname@example.org; email@example.com
Introduction: The 6-phosphogluconate dehydrogenase (6PGD) was upregulated in many solid cancers and plays an important role in tumorigenesis. In the present study, we want to discover an old drug as an inhibitor of 6PGD for suppressing tumor growth.
Methods: We determined the expression of 6PGD in cancer tissues using Gene Expression Omnibus (GEO) profiles and explored the importance of 6PGD expression in cancer progression by using Kaplan–Meier Plotter. We identified Ebselen as a 6PGD inhibitor by using 6PGD in vitro enzyme activity assay. Cell viability, cell proliferation, tumor growth and cell metabolism assay were used to explore the role of 6PGD and its inhibitor in cancer cells.
Results: We found that the expression of 6PGD was upregulated in different cancer tissues and it can promote tumorigenesis. Here, we analyzed our 6PGD inhibitor screening data again and found an old drug Ebselen, which blocks cancer cell proliferation and tumor growth by inhibiting 6PGD enzyme activity, while knocking down 6PGD would partially abolish the inhibition of Ebselen on cell proliferation and cell metabolism.
Conclusion: Our results suggested that the conventional drug Ebselen could serve as a novel inhibitor of 6PGD for suppressing cancer growth by inhibiting 6PGD enzyme activity.
Keywords: Ebselen, 6PGD, oxidative pentose phosphate pathway, cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]